Tesmilifene modifies brain endothelial functions and opens the blood-brain/blood-glioma barrier

Journal of Neurochemistry

Volumn 134, Issue 6, 2015, Pages 1040-1054

  Walter, Fruzsina R ^a   Veszelka, Szilvia ^a   Pásztõi, Mária ^a,b   Péterfi, Zoltán A ^c   Tõth, András ^d   Rákhely, Gábor ^d   Cervenak, Lászlõ ^e   Ábrahám, Csongor S ^a   Deli, Mária A ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

blood brain barrier; brain endothelial cells; glioma; permeability; tesmilifene; tight junctions

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TESMILIFENE; TIGHT JUNCTION PROTEIN; ANTIHISTAMINIC AGENT; DIPHENYL ETHER DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GLIOMA; MALE; MEMBRANE PERMEABILITY; MICROVASCULATURE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TIGHT JUNCTION PROTEIN GENE; ANIMAL; BRAIN TUMOR; CAPILLARY PERMEABILITY; CELL CULTURE; COCULTURE; DISEASE MODEL; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; WISTAR RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; GLIOMA; HISTAMINE ANTAGONISTS; IMMUNOHISTOCHEMISTRY; MALE; PHENYL ETHERS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84941803098     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13207     Document Type: Article

References (51)

1. Aas A. T., Brun A., Blennow C., Strömblad S., and, Salford L. G., (1995) The RG2 rat glioma model. J. Neurooncol. 23, 175-183.
2. Abbott N. J., Patabendige A. A., Dolman D. E., Yusof S. R., and, Begley D. J., (2010) Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13-25.
3. Bart J., Groen H. J., Hendrikse N. H., van der Graaf W. T., Vaalburg W., and, de Vries E. G., (2000) The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat. Rev. 26, 449-462.
4. Brandes L. J., (2008) N, N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer. Hum. Exp. Toxicol. 27, 143-147.
5. Brandes L. J., and, Hermonat M. W., (1984) A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver microsomes. Biochem. Biophys. Res. Commun. 123, 724-728.
6. Brandes L. J., and, Hogg G. R., (1990) Study of the in-vivo antioestrogenic action of N, N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine HCl (DPPE), a novel intracellular histamine antagonist and antioestrogen binding site ligand. J. Reprod. Fertil. 89, 59-67.
7. Brandes L. J., Gerrard J. M., Bogdanovic R. P., Lint D. W., Reid R. E., and, LaBella F. S., (1988) Correlation of the antiproliferative action of diphenylmethane-derivative antiestrogen binding site ligands with antagonism of histamine binding but not of protein kinase C-mediated Ωphorylation. Cancer Res. 48, 3954-3958.
8. Brandes L. J., LaBella F. S., and, Warrington R. C., (1991) Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J. Natl Cancer Inst. 83, 1329-1336.
9. Brandes L. J., Simons K. J., Bracken S. P., and, Warrington R. C., (1994) Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N, N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents. J. Clin. Oncol. 12, 1281-1290.
10. Brasier A. R., (2006) The NF-kappaB regulatory network. Cardiovasc. Toxicol. 6, 111-130.
11. Camire R. B., Beaulac H. J., Brule S. A., McGregor A. I., Lauria E. E., and, Willis C. L., (2014) Biphasic modulation of paracellular claudin-5 expression in mouse brain endothelial cells is mediated through the phosphoinositide-3-kinase/AKT pathway. J. Pharmacol. Exp. Ther. 351, 654-662.
12. Deli M. A., (2009) Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta 1788, 892-910.
13. Deli M. A., Dehouck M. P., Ábrahám C. S., Cecchelli R., and, Joõ F., (1995) Penetration of small molecular weight substances through cultured bovine brain capillary endothelial cell monolayers: the early effects of cyclic adenosine 3',5'-monophosphate. Exp. Physiol. 80, 675-678.
14. Deli M. A., Németh L., Falus A., and, Ábrahám C. S., (2000) Effects of N, N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine on the blood-brain barrier permeability in the rat. Eur. J. Pharmacol. 387, 63-72.
15. Deli M. A., Abrahám C. S., Niwa M., and, Falus A., (2003) N, N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine increases the permeab-ility of primary mouse cerebral endothelial cell monolayers. Inflamm. Res. 52 (Suppl 1), S39-S40.
16. Deli M. A., Ábrahám C. S., Kataoka Y., and, Niwa M., (2005) Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell. Mol. Neurobiol. 25, 59-127.
17. Demeuse P., Fragner P., Leroy-Noury C., Mercier C., Payen L., Fardel O., Couraud P. O., and, Roux F., (2004) Puromycin selectively increases mdr1a expression in immortalized rat brain endothelial cell lines. J. Neurochem. 88, 23-31.
18. Doolittle N. D., Miner M. E., Hall W. A., et al., (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88, 637-647.
19. Dubois L. G., Campanati L., Righy C., et al., (2014) Gliomas and the vascular fragility of the blood brain barrier. Front. Cell. Neurosci. 8, 418.
20. Duckles S. P., and, Krause D. N., (2007) Cerebrovascular effects of oestrogen: multiplicity of action. Clin. Exp. Pharmacol. Physiol. 34, 801-808.
21. Erdlenbruch B., Alipour M., Fricker G., Miller D. S., Kugler W., Eibl H., and, Lakomek M., (2003) Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br. J. Pharmacol. 140, 1201-1210.
22. Fischer S., Wiesnet M., Renz D., and, Schaper W., (2005) H2O2 induces paracellular permeability of porcine brain-derived microvascular endothelial cells by activation of the p44/42 MAP kinase pathway. Eur. J. Cell Biol. 84, 687-697.
23. Georges E., Lian J., and, Laberge R., (2014) A tamoxifen derivative, N, N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine, selectively targets P-glycoprotein-positive multidrug resistant Chinese hamster cells. Biochem. Pharmacol. 90, 107-114.
24. González-Mariscal L., Tapia R., and, Chamorro D., (2008) Crosstalk of tight junction components with signaling pathways. Biochim. Biophys. Acta 1778, 729-756.
25. Guo Q., Wang G., and, Namura S., (2009) Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice. J. Cereb. Blood Flow Metab. 30, 70-78.
26. Hülper P., Veszelka S., Walter F. R., Wolburg H., Fallier-Becker P., Piontek J., Blasig I. E., Lakomek M., Kugler W., and, Deli M. A., (2013) Acute effects of short-chain alkylglycerols on blood-brain barrier properties of cultured brain endothelial cells. Br. J. Pharmacol. 169, 1561-1573.
27. Inamura T., and, Black K. L., (1994) Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J. Cereb. Blood Flow Metab. 14, 862-870.
28. Jordan V. C., (2014) Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr. Relat. Cancer 21, R235-R246.
29. Kilic E., Kilic U., Wang Y., Bassetti C. L., Marti H. H., and, Hermann D. M., (2006) The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB. J. 20, 1185-1187.
30. Kiss L., Walter F. R., Bocsik A., Veszelka S., Ózsvári B., Puskás L. G., Szabõ-Révész P., and, Deli M. A., (2013) Kinetic analysis of the toxicity of pharmaceutical excipients Cremophor EL and RH40 on endothelial and epithelial cells. J. Pharm. Sci. 102, 1173-1181.
31. Kojima H., Sakurai K., Kikuchi K., Kawahara S., Kirino Y., Nagoshi H., Hirata Y., and, Nagano T., (1998) Development of a fluorescent indicator for nitric oxide based on the fluorescein chromophore. Chem. Pharm. Bull. 46, 373-375.
32. Kroeger E. A., and, Brandes L. J., (1985) Evidence that tamoxifen is a histamine antagonist. Biochem. Biophys. Res. Commun. 131, 750-755.
33. Lászlõ V., Rothe G., Hegyesi H., Szeberényi J. B., Orsõ E., Schmitz G., and, Falus A., (2001) Increased histidine decarboxylase expression during in vitro monocyte maturation; a possible role of endogenously synthesised histamine in monocyte/macrophage differentiation. Inflamm. Res. 50, 428-434.
34. Liu J., Tu D., Dancey J., Reyno L., Pritchard K. I., Pater J., and, Seymour L. K., (2006) Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. Breast Cancer Res. Treat. 100, 263-271.
35. Muldoon L. L., Soussain C., Jahnke K., et al., (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25, 2295-2305.
36. Nakagawa S., Deli M. A., Kawaguchi H., Shimizudani T., Shimono T., Kittel Á., Tanaka K., and, Niwa M., (2009) A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 54, 253-263.
37. Neuwelt E. A., Goldman D. L., Dahlborg S. A., Crossen J., Ramsey F., Roman-Goldstein S., Braziel R., and, Dana B., (1991) Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J. Clin. Oncol. 9, 1580-1590.
38. Neuwelt E., Abbott N. J., Abrey L., et al., (2008) Strategies to advance translational research into brain barriers. Lancet. Neurol. 7, 84-96.
39. On N. H., and, Miller D. W., (2014) Transporter-based delivery of anticancer drugs to the brain: improving brain penetration by minimizing drug efflux at the blood-brain barrier. Curr. Pharm. Des. 20, 1499-1509.
40. Packer R. J., Krailo M., Mehta M., Warren K., Allen J., Jakacki R., Villablanca J. G., Chiba A., and, Reaman G., (2005) A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer 104, 1968-1974.
41. Parrish K. E., Sarkaria J. N., and, Elmquist W. F., (2015) Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier. Clin. Pharmacol. Ther. 97, 336-346.
42. Perrière N., Demeuse P., Garcia E., et al., (2005) Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J. Neurochem. 93, 279-289.
43. Raghavan D., Brandes L. J., Klapp K., Snyder T., Styles E., Tsao-Wei D., Lieskovsky G., Quinn D. I., and, Ramsey E. W., (2005) Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J. Urol. 174, 1808-1813; discussion 1813.
44. Régina A., Demeule M., Laplante A., Jodoin J., Dagenais C., Berthelet F., Moghrabi A., and, Béliveau R., (2001) Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev. 20, 13-25.
45. Reyno L., Seymour L., Tu D., et al., National Cancer Institute of Canada Clinical Trials Group Study MA.19. (2004) Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J. Clin. Oncol. 22, 269-76.
46. Seifert S., and, Sontheimer H., (2014) Bradykinin enhances invasion of malignant glioma into the brain parenchyma by inducing cells to undergo amoeboid migration. J. Physiol. 592, 5109-5127.
47. Stone K. P., Kastin A. J., and, Pan W., (2011) NFAB is an unexpected major mediator of interleukin-15 signaling in cerebral endothelia. Cell. Physiol. Biochem. 28, 115-124.
48. Tõth A. E., Tõth A., Walter F. R., et al., (2014) Compounds Blocking Methylglyoxal-induced Protein Modification and Brain Endothelial Injury. Arch. Med. Res. 45, 753-764.
49. Uchida Y., Ohtsuki S., Katsukura Y., Ikeda C., Suzuki T., Kamiie J., and, Terasaki T., (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117, 333-345.
50. Weyerbrock A., Walbridge S., Pluta R. M., Saavedra J. E., Keefer L. K., and, Oldfield E. H., (2003) Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. J. Neurosurg. 99, 728-737.
51. Xu F. Y., Queen G., Brandes L., and, Hatch G. M., (2007) The phospholipidosis-lnducing potential of the chemopotentiating drug, N, N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE, tesmilifene) correlates with its stimulation of phosphatidylserine synthesis and exposure on the plasma membrane in MCF-7 breast cancer cells. Proc. West. Pharmacol. Soc. 50, 61-63.